Gan & Lee and Menarini Advance Bofanglutide in Europe
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Beijing, China & Florence, Italy, September 3, 2026 Gan & Lee Pharmaceuticals and The Menarini Group have entered into...
BAGSVÆRD, Denmark, June 11, 2026 Novo Nordisk announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has...
BAGSVAERD, Denmark, May 12, 2026 Novo Nordisk announced new clinical findings at the 2026 European Congress on Obesity (ECO...
